U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

BROOKHAVEN NATIONAL LABORATORY WORK GROUP

+ + + + +

WEDNESDAY
MARCH 6, 2013

+ + + + +

The Work Group convened telephonically at 2:30 p.m., Eastern Standard Time, Josie Beach, Chair, presiding.

PRESENT:

JOSIE BEACH, Chair HENRY ANDERSON, Member BRADLEY P. CLAWSON, Member WANDA I. MUNN, Member GENEVIEVE S. ROESSLER, Member

ALSO PRESENT:

TED KATZ, Designated Federal Official RON BUCHANAN, SC&A
GRADY CALHOUN, DCAS
JOE FITZGERALD, SC&A
JENNY LIN, HHS
JAMES NETON, DCAS

A-G-E-N-D-A

Welcome and Roll Call, Introductions	. 4
Work Group Discussion on Post-1993 Dose Reconstruction Feasibility	. 7
- DCAS Dose Reconstruction Methods for Four Sample Cases	
- Work Group Recommendations on Path Forward	b
March Board Meeting Plans	57

P-R-O-C-E-E-D-I-N-G-S

2:31 p.m.

MR. KATZ: Welcome, everyone. This is the Advisory Board on Radiation Worker Health. Let's get started. We have a fairly short time frame although we don't have a long agenda either. But let's get started with roll call. We're speaking about a specific site conflict of interest. How about we go through it. Board Members.

(Roll call.)

MR. KATZ: So, there's an agenda for the meeting that's posted on the NIOSH website under the Board section under meetings for today. There's no material posted and, Josie, it's your meeting.

CHAIR BEACH: Okay, thank you. So just to touch up on February 14. The Work Group has a phone conference call. We asked NIOSH, Grady, to go back and prepare some proposed approaches for dose reconstruction for four sample cases. He did deliver those

NEAL R. GROSS

last week	for	Case	Α,	В,	D	and	Ε.
-----------	-----	------	----	----	---	-----	----

On the agenda it talks about the four methods and then Work Group methods, a path forward recommendation and then March meeting plans. I also want to just real briefly touch on the Site Profile issues. I don't want to spend whole lot of time because I know our call is limited but I just want to go make sure we're moving forward with some of those also. So we'll touch on that before the end of the call.

And Grady, if you would like to go ahead and since you put out the cases for us, the history, if you just want to start with those.

MR. CALHOUN: Sure. I guess what I'll do is I'll just, I'll go Case A through E. And I'll stop after each one and then we can kind of discuss it and let me know.

CHAIR BEACH: Okay.

MR. CALHOUN: The first one I'll start out with is Case A. I hope everybody

NEAL R. GROSS

has a chance to look at this because I'd like to say that this was a really good exercise, actually, for me too because it kind of solidified my confidence in the records that we have by looking at things that really are a little bit above and beyond what records were but they were submitted at Brookhaven with our records request.

So case number A or letter A, the individual has verified employment from `56 to `95. Worked technician with later transferred accelerators, to cold neutron moderator facility. The records, dosimetry records that we have are external dosimetry records from 1956, `57, with a break in `58. Then we have `59 through `95.

We also have tritium urinalysis from October of `89 through October of `92. We have in vivo exams beginning in December `83 and they go into September of `95.

Okay, based on the latest SC&A -MEMBER ANDERSON: This is Andy. I

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1 just want to let you know that I'm here. 2 CHAIR BEACH: Great. Thanks, Andy. 3 MR. CALHOUN: Based on the latest 4 SC&A report the concerns seem to be that there were no bioassay records for `94 and `95. 5 6 he retired in `95. Our conversation, the last -- or 7 whenever we had it, awhile ago. Our last 8 conversation I'll say. So we talked about --9 10 I put forth that I believed that it was quite possible that the individual wasn't monitored 11 because he didn't need to be monitored. 12 13 at that time I had no -- that actually said that he didn't need to be monitored. 14 15 keep in mind that Now, 16 documentation is really rare to find at any But lo and behold I found it. site. 17 that as Attachment Al. And in Attachment Al 18 19 what we have is a HFBR bioassay program. 20 And just to remind everybody, these five cases were selected by SC&A because they 21

had at least some employment at the HFBR, at

1	the High Flux Beam Reactor Facility. So the
2	review was done by SC&A to determine there
3	was an assumption made that tritium monitoring
4	that tritium monitoring would be required.
5	And then they looked monitoring records
6	weren't there after the 1993 SEC period in
7	particular.
8	COURT REPORTER: This is the court
9	reporter. Is anybody else getting
10	interference on the call?
11	CHAIR BEACH: Yes.
12	MR. KATZ: Yes. Let me just ask
13	everybody except for Grady because Grady's
14	speaking. Everybody else should mute your
15	phone. And if you don't have a button press
16	*6. That will mute your phone. Press *6
17	again, it'll take you off mute. Because we
18	have about 20 people on this call so not
19	everybody's registered, listening to speak.
20	Mute your phone. Thanks. *6, okay.
21	MEMBER MUNN: Ted, this is Wanda.

be getting some

may

You

22

from my

static

feedback even when I'm on mute. I'm going to sign off for the moment. I'm only about 5 minutes from home. I'll be back on. Thank you. Bye bye.

MR. KATZ: Okay. Okay, carry on.

MR. CALHOUN: I don't know, I'm still getting that chirp. But anyway I'm going to continue.

Basically where I left off is there was some discussion. I believe that it was possible that the individual was not monitored past 1992 for tritium that he didn't need to be monitored.

And I didn't have proof of that but actually when I looked through we found a document and I included that as Attachment A1.

And what that is, it is a 1992 document that explains what the monitoring requirements are and it includes a 6-month exposure and it gives a list of individuals. And it says, it gives their last 6 months of tritium dose and it states whether or not they need to be on

routine tritium monitoring.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

And this individual, his name was [identifying information redacted] and he is not -- well, never mind. He does not need to be monitored. He was on that document, he's one, two, three, four people up. And it states that he does not need to be on his monitoring. And the previous 6 months of tritium monitoring was zero.

So I don't really think I need to go any further on this case because that pretty much nailed it. There is some other information that talks about him moving to a different facility where monitoring wouldn't be required but the key for this case is there documented formal evaluation as was а whether or not routine monitoring was required and the determination was made that no, it does not. So I'm going to stop on that one.

CHAIR BEACH: This is Josie.

Thanks, Grady. Any questions on Case A from

Work Group Members or SC&A?

NEAL R. GROSS

1	MR. FITZGERALD: No. This is Joe.
2	I think we found the documentation to be
3	persuasive as well. I think that would be our
4	comment.
5	CHAIR BEACH: Okay. So an overall
6	comment. Okay. Yes, and Grady, I really
7	appreciated the write-up that you did. It was
8	very helpful. And I especially liked being
9	able to have those attachments to reference
LO	back. So good job there.
L1	MR. CALHOUN: You know what, it was
L2	very helpful for me too.
L3	CHAIR BEACH: Good.
L4	MR. CALHOUN: It helped me feel
L5	better about it, so.
L6	MEMBER ROESSLER: It was what we
L7	were looking for.
L8	MR. CALHOUN: Right.
L9	CHAIR BEACH: Yes.
20	MR. CALHOUN: Okay, I'm going to
21	move on to case B then if that's okay.
22	CHAIR BEACH: Okav.

MR. CALHOUN: All right. Hold on,
I'm going to delete something here because
I've got so many files open it's driving me
crazy.

Okay, case B. We have verified employment from [identifying information redacted] of `86 to present. Per the assisted telephone interview he worked as [identifying information redacted], and he worked at the HFBR and a medical research reactor.

The records that we have received from Brookhaven include external radiation -- records from -- to 2009. Urinalysis from 2/87 to 3/01, February 1987 to March 2001. We've got in vivo exams beginning in December of `86 and going at least through October of `99.

Per the latest evaluation the main concern was that we were missing -- they thought that we were missing tritium monitoring for the month of June of 1994 and several months in 1995. The in vivo did not seem to be an issue with this case.

So, what we have found, we've got more than 170 individual tritium samples taken for this guy, '94 through '01, and all of the months in question either have a monthly report or a summary of multi months or even an annual summary.

But one of the keys is Attachment B1. And this attachment is actually for 1995. And in 1995 the concern was that there were one, two, three, four, five, six, seven, eight months missing. And what I found, that there actually were not eight months missing. What happened was he just wasn't monitored every single month.

And this Attachment B1 gives the date of the individual sample and the number of days in between those samples. So what's that telling us is there's not missing data. And so there's not missing data. And the concern was that there was missing data. And since there's not missing data we can do the dose reconstruction by assuming a missed dose

or positive doses were there throughout the entire period of his monitoring.

And even if there was some months assumed to be missing we could still do that. But this document clearly shows that there's no missing data in between those months as we had thought. And again, this is one of those pieces of information I hadn't seen before. It was provided to me by Brookhaven.

There are hundreds and hundreds of pages of documentation to go through. And so this is one of those pieces I didn't see until I started going through this. So we don't have anything past -- the concern was `94-`95 and it looks like we've pretty much put those to bed with this in my opinion.

The guy did later transfer to the collider/accelerator department where monitoring would be required but the concern of these `94 and `95 is I think pretty much answered by Attachment B1.

Any questions on that or comments?

NEAL R. GROSS

1	MR. FITZGERALD: Yes, Grady, Joe.
2	I have one question. Would that be you
3	talked about the hundreds of pages of
4	documentation. We certainly saw the same
5	thing. Is that body of records, is that going
6	to be available in a form say a dose
7	reconstructor could have ready access to and
8	be able to make heads or tails of it? It
9	sounds like the information may be there but
10	I'm wondering how easily accessible it might
11	be.
12	MR. CALHOUN: Yes, I mean it's in
13	the same exact form, they're just bigger
14	records than any other response we received
15	from a Department of Energy facility. And
16	this isn't the only Department of Energy
17	facility that may provide hundreds of pages of
18	records.
19	MR. FITZGERALD: Right. So the
20	process would probably be the same.
21	MR. CALHOUN: It would be exactly
22	the same because it's listed as a DOE

response.

MR. FITZGERALD: Right. Now, just this is for the Work Group. Now originally when we, you know, certainly when Ron proposed and we came up with this sample process the whole intent was to test, challenge if you may the completeness of the records past `93 in terms of being able to rationalize and support DR.

And I think this is exactly what we were hoping to see which is a demonstration that in this body of records, the additional records, there is some way to explain gaps and also to provide a basis for dose reconstruction. So this is all in keeping with what we were trying to do with these samples.

And Brookhaven is a difficult one to sample because of the -- just a lack of information sort of guiding who was routinely monitored and for what. I think using these five cases is a good way to go. So I think

NEAL R. GROSS

l	
1	this one, again, we felt the challenge was met
2	in terms of the records being available to
3	rationalize the gaps. So again I think we're
4	okay with this one.
5	CHAIR BEACH: Okay, this is Josie.
6	Thanks, Joe. Any other Work Group Members,
7	questions on Case B?
8	MEMBER ROESSLER: Joe, are you okay
9	with Case A also?
10	MR. FITZGERALD: Well, Case C, and
11	I let Ron
12	MEMBER ROESSLER: Case A which we
13	already covered. Are you
14	MR. FITZGERALD: Yes, we already
15	covered and I think that came out as being
16	complete in terms of the records. You know,
17	originally the May 22 memo authored by Ron
18	I should let Ron talk about this
19	identified, went through a process to identify
20	five cases that involved individuals at
21	Brookhaven during that time frame that should
22	have been routinely monitored based on the

1	location of their work and other information.
2	I think that one turned out to have a
3	complete set of data in any case. Is that
4	right, Ron?
5	DR. BUCHANAN: Yes. Case C had all
6	12 months of tritium every year and whole body
7	counts for every year. So Case C wasn't an
8	issue.
9	CHAIR BEACH: I think Gen asked
LO	about Case A, the very first one, Joe.
11	MR. FITZGERALD: Oh, I'm sorry. I
L2	thought she said C.
L3	MEMBER ROESSLER: I'm trying to
L4	the line is bad.
L5	MR. FITZGERALD: Yes.
L6	MEMBER ROESSLER: I'm just trying
L7	to I guess establish are you okay with Case A,
L8	Case B and then also Case C at this point.
L9	MR. FITZGERALD: Yes. Again, the
20	supporting documentation, the additional
21	records that Grady had cited last year seemed
22	to be sufficient to answer the questions that

1	we posed. You know, what are these gaps, why
2	would they exist and are they real. And if
3	they are in fact real can they be explained in
4	terms of the assignment of the worker
5	involved. And so far certainly on A, B and C
6	we're satisfied.
7	MEMBER ROESSLER: Okay, thanks.
8	CHAIR BEACH: Okay, if there's no
9	other questions, Grady, please carry on with
10	Case D.
11	MR. CALHOUN: Okay, Case D. Let me
12	close out real quick. All right.
13	Okay. Case D is kind of a
14	different one. Case D, now remember that
15	these five cases were selected because there
16	was some inkling at least that there was
17	these individuals were assigned to or
18	frequently worked at the High Flux Beam
19	Reactor which is one of the main sources of
20	tritium for that facility.
21	This individual did not. She
22	mentions in her CATI that she actually was

there, but when you look at her medical records and whatnot she was a scientist that worked in isotope separation and she primarily worked in the isotope separation lab.

However, there was monitoring records there and let me tell you some of the things here. She had verified employment from 1989 through 2004. She worked as a scientist in various labs, accelerators and reactor areas.

One thing I forgot to put in here that I should have is that in her CATI there's a bunch of radioisotopes listed as to were you or were you not exposed to them. The tritium is marked no, she was not exposed to tritium.

However, here's what we've got. The dosimetry records that we see are -- we've got external radiation dose from 1989, November of `89 to -- of 2005. We only have tritium urinalysis from -- in one month and that was 1990, October. So she only had one or two samples.

She had some other urinalysis for different radionuclides in 1990 as well and that involves a gamma scan because she was involved with some exotic type of radionuclides, things that weren't as typical as say -- and some of the other fission products that you might see at a reactor.

She had a multitude of in vivo exams but they appear to be very much incident driven. She had them in 1990, 1993, `95, `96, `99, `01, `02, `03 and `04. She has multiple contamination that are well documented. In - `93, `96, `99 and 2000.

We also have a calculation using the code for internal dosimetry lovingly known as CIND to us. And that was done in 1992. There was a thought that she had done a cobalt-57 uptake. And we also have like I said a gamma scan in October of `90.

Now, the latest Work Group SC&A review was concerned because tritium bioassay records do not exist through `94 through `99.

NEAL R. GROSS

In vivo records don't exist for `94, `97 and `98.

Now, I think that the tritium is not as significant of a deal because she didn't work at HFBR. That's not a place that she was routinely assigned to. She never shows up on any of the bioassay records of people that were working at that facility. And like I said, her medical records show that she was working at a different lab.

Okay. We've got the external records. We believe those are all complete. She worked primarily in the target processing lab where tritium monitoring would not be required.

We've got 14 different in vivo exams from `90 to 2000. And I didn't include a bunch of those but we've got -- you can see that there's notations. Let me pull one up to see what it says. There's notations and even reports that talk about incidents that she may have been involved in and how these incidents

NEAL R. GROSS

were followed up. Some of the incidents were identified because she was contaminated and she was walking out of the facility. And follow-up survey decided or found that she was contaminated and identified the contaminants and she had to end up multiple whole body counts and even gamma scans of urinalysis.

example of a whole body count but she was potentially involved in a scandium-47 incident. And that's just, really just for your information. It shows that these really exotic nuclides were the reason that she was monitored and this was pretty much the result of an incident. And her monitoring, internal monitoring appears to be incident driven.

We've got some other dosimetry evaluations because somebody said, you might say, well, if she was contaminated do we need to -- were any follow-up bioassays required. And one of these events that I have that occurred in 1999 there's actually -- in the

Contamination Report it -- what the contamination levels were, where they were on her body. And it says what is additional -- is a bioassay required and if so what kind. And in this case it is checked no, but in other cases we actually did have a bioassay that was Attachment D2. And then I -- D3 says. Okay?

D3 is a similar situation although it occurred in 2000. And again was bioassay required. In this case it was not. But this different it different was а contamination event. It talks about the contamination levels. And this one was actually on the skin and it wasn't on the clothing. I think the last one might have been just on the clothing.

And basically the way we will do dose reconstruction in this case, we would not assign tritium other than anything that might show up in ambient except for the year that she was monitored for tritium. Even though

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

that is -- SEC period we would use that data.

And other radionuclides, the fission products and the exotics, we've got fission products, the MDA the minimum detectable activities, and we would assign those with the in vivo that we have. And we would assign either missed or positive doses based on the result of those.

In addition, we've got detailed analysis of radionuclides other than routine radionuclides that we would see. And we would and actually did include those in the dose reconstruction. This individual was actually I think comped through the SEC.

But that's all I have on -- let's see, make sure I got it right here. Multiple documents -- examinations were provided. Yes, we don't feel that there were any records missing for this individual. Because she was working in a different type of environment other than HFBR it appears here that she had significant and detailed bioassay, both

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

urinalysis and in vivo counts. And those would certainly be sufficient for us to do dose reconstruction on this individual. I don't have anything else on that one.

CHAIR BEACH: Okay. This is Josie again. Thanks, Grady. Any questions on Case D, Work Group Members or SC&A? Or comments?

MR. FITZGERALD: Yes, this is Joe again. Just one quick comment. You know, compared with the previous years going back into the eighties and nineties, and I spent some time at Brookhaven looking through these records. You know, I think this eventually is just a change in the nature of the records.

You can tie an individual to a location, to a time frame, to a source term which is something when we were going through the records in the eighties and nineties, or I should say the seventies and eighties, you just couldn't do it. The records wouldn't allow you to do it. So I think this is a

NEAL R. GROSS

significant shift in what we were looking for in terms of a post-SEC time frame. So again I think that's the lesson or the evidence to take from this.

CHAIR BEACH: Okay.

MR. CALHOUN: And I don't want to be here either, Joe, but if -- like I said, this has been really helpful to me too because I'm looking at more than just the dose. You know, I took the time to actually, you know, you look at the whole body count and you see the notations and you see where they worked, and you look at their medical records. And so it adds -- it's an eye opener for me.

MR. FITZGERALD: Yes. And just pre nineties period we were seeing whole chunks of data missing.

MR. CALHOUN: Right.

MR. FITZGERALD: A lot of it was disposed of or taken back by a researcher and it was just missing. So, you know, you might have somebody in a case they were at a

1 facility but you could not tie any data to 2 So again I think that's the contrast 3 that we were looking for. MR. CALHOUN: I will move on to E. 4 CHAIR BEACH: Okay. 5 6 MR. CALHOUN: You ready for that 7 Just give me a second again. I've got to -- okay, there's that. I'm talking to 8 myself but I do that a lot. Okay, E. 9 10 E, the verified employment individual [identifying information 11 is redacted lof `61 12 through [identifying information redacted] of 2003. 13 Per the computer-assisted telephone interview the E 14 15 worked in chemical management with a fixed 16 barcode. The chemicals and various labs and He reported he did that from `92 to 17 whatnot. Then he also -- in -- HFBR from `94 to 18 19 2001 performing rad surveys. And he also --20 urine samples -- tritium analysis. The records that we received, the 21

external records go from `61 to `63.

22

Then

there's a gap and we go from `92 to 2003. We have tritium urinalysis beginning November of 1995 and it goes through or into at least October of 2001.

We've got whole body or in vivo exams for `95, `97, `98, `99 and 2000. The latest concerns that we have about this individual is that we were missing tritium analysis for `94, for all of `94 and for January into December of `95. And that there are no records of in vivo monitoring for `94 and `96.

Okay, this is another kind of a fun one that it took a little detective work. But we found out through his records and the -- they complied with the dosimetry request. These aren't any funky records that we found on a capture. But he didn't really start working at the HFBR until October of `95.

And how we can find that is that I attached Attachment El is the first one. And these are visitor logs. And the individual

NEAL R. GROSS

was required, escorted into an area. And you have to sign in on these every day. And he had to be escorted into this area and he was on three separate occasions between September 14, '95 and October 10 of 1995.

And then -- have is attachment E2 is an indoctrination sheet. And what we found is that this indoctrination sheet is the training that allows the individual to begin working at a facility at the HFBR unescorted. And so this individual signed off on this in October 10 of '95 and the estimated time working at this facility was described as indefinite after October 1995.

really Now, very not coincidence. In vivo exams begin in November of 1995. And when you pull out that in vivo exam that happened in, you know, a month after, less than а month after he was indoctrinated to be allowed to work there unescorted the notation in there is that he was Reactor Division annual new HD transfer

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

from the Department of Applied Technology. So he was working in an area of the Department of Applied Technology and he was transferred to the Reactor Division which would be the HFBR as notated on in vivo count in November of 1995.

He also started, let's see. We also see that the -- the tritium urinalysis begins November of `95 as well. And -- very, very many tritium urinalysis after that point. But the reason that we did not have that is because he wasn't working at the HFBR October of 1995.

certainly have enough tritium results and in vivo counts to reconstruction. Basically what we would do is would include would ___ we reconstruct tritium using all of the tritium monitoring that we have and we would assign missed and positive based on those results. And we would do the same thing with the in vivo exam. those would be based missed on and any

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

positives although I don't believe he had any 1 2 in vivo exams. And that's how we would do the 3 reconstruction for internal at that 4 point. 5 Now, there was one concern 6 between `95 and `97 -- we didn't find an in vivo result for 1996 but we do have one for 7 `95 and we have one for `97. And the interval 8 between those is 18 months. And you certainly 9 10 make assumptions with missed dose 11 between there. And that certainly 12 acceptable for do way to dose us 13 reconstruction, missed dose. So, let's make sure I didn't miss 14 15 anything else with that one. No, that's all I 16 have with Case E as well now. CHAIR BEACH: This one appeared to 17 be the most challenging of the four to me. 18 19 MR. CALHOUN: don't know, 20 thought it was pretty conclusive with the indoctrination sheet. Because the 21

HFBR employment and whether

thing,

1	routine bioassay was required.
2	CHAIR BEACH: Right.
3	MR. CALHOUN: Didn't start working
4	there until October. I mean, and internal
5	the in vivo and tritium both start in November
6	of `95 and his indoctrination was October of
7	`95.
8	MEMBER ROESSLER: That's pretty
9	clear-cut.
10	CHAIR BEACH: Yes, any questions?
11	Comments? Work Group Members or SC&A?
12	MEMBER ROESSLER: Josie, are you
13	satisfied on this one?
14	CHAIR BEACH: Yes.
15	MEMBER ROESSLER: Now that he's
16	gone through it.
17	CHAIR BEACH: Yes. I'm satisfied
18	with all of them, actually. I thought that
19	was a good exercise. I appreciate NIOSH for
20	taking that extra step on all of these. It
21	was helpful.
22	MEMBER ROESSLER: Yes, I appreciate

it too. I know it was a lot of work and Grady, I know you had a busy schedule. But I think before we really didn't have what we needed to feel confident about this.

MR. CALHOUN: I feel better about it too. So, it was okay, you know. You know what's funny is Stu always says if it wasn't for the last minute nothing would ever get done. And boy, those 2 weeks, I had 2 full weeks of last minute, so.

CHAIR BEACH: You got a lot done. You even managed to answer my Site Profile question so that is awesome. Anything -- or I don't know if you're still with us, Andy.

MEMBER ANDERSON: Yes, my question is that are this new set of records going to be easily searchable. It sounds like you put a tremendous amount of effort in it and if this now goes into being used how easy it find is going to be to these documentations?

MR. CALHOUN: I've got a thought on

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	that. And first of all, like Joe said, they
2	will all be in the same format as everything
3	else. But what this exercise does is we don't
4	have to go back and look for indoctrination
5	sheet. This shows documentation that we have
6	and that the dosimetry that was provided is
7	good. We do have all that information to it,
8	for it and they are required, we are required
9	to look at the DOE information as provided to
10	us before we do a dose reconstruction. So it
11	is, it is all there in a normal format that
12	any other providing information.
13	MEMBER ANDERSON: Okay, good.
14	Thanks.
15	DR. BUCHANAN: Yes, this is Ron
16	Buchanan with SC&A. What I did when I
17	reviewed these cases originally was to say,
17 18	reviewed these cases originally was to say, okay, identify. It looked like there were
18	okay, identify. It looked like there were

reconstructor would receive, do the dose

this material 1 reconstruction. So is 2 available. This isn't something that Grady 3 had to go out and search for individually. And so what I did is I used the 4 5 protocol that we used on Task 4 to audit the 6 NIOSH dose reconstruction and say did it meet 7 the standards of that protocol. And I found that it did, that when you go back and look 8 through all the hundreds of pages and find 9 10 out. And the dose reconstructor will do 11 12 He goes back and looks and see if this. 13 there's gaps and see how it should be filled in or if it's justified or whatever. 14 And so 15 as far as my experience of doing the audits on 16 the dose reconstruction I found that it did satisfy that protocol. 17 18 MEMBER ANDERSON: Okay. 19 CHAIR BEACH: Thanks, Ron. 20 MEMBER ROESSLER: Josie, you mentioned going on to the Site Profile issues 21

to

come

going

are

we

but

22

up

with

recommendations for the meeting, the Board meeting?

CHAIR BEACH: Well, that's going to be a question that I was going to just ask Ted how to proceed. Because we still have SEC issues. And remember back in May, we divided them into the most relevant ones. I believe there was three, the remaining primary findings. And we tried to push ahead with the SEC issues. So, I guess we have to decide on the end date or agree with the end date but I'm not sure how to go forward with that, so.

MR. KATZ: Hi, Josie, can you hear me?

CHAIR BEACH: Yes.

MR. KATZ: So, this is Ted. So I mean, if this closes out the question of the '93 period, that is the question that was left open for the Work Group to report out to the Board on in terms of data accuracy. So I mean if you reached a conclusion and you all sound unanimous that these records seem good, then

1	you would need to make a recommendation in
2	line with that to the Board so that they can
3	then close out the Board consideration of SEC
4	Petition.
5	CHAIR BEACH: Okay. So the
6	question I have then is, we are considering
7	the `94 to 2007 time period. We do have a
8	couple of Site Profile issues that could have
9	SEC implications but I'm not 100 percent sure.
10	I'm assuming, based on this, we can close out
11	those years. But does that completely close
12	out all SEC items?
13	MR. KATZ: Well, that would only
14	oh, go ahead.
15	MEMBER CLAWSON: This is Brad. I'm
16	trying to remember what those other issues are
17	that we had. They were outside the what
18	were they dealing with?
19	CHAIR BEACH: Well, and Grady can
20	talk. Grady went by and he sent me an email
21	because I asked about the Site Profile issues.
22	And the three primary ones he sent a report

1	out answering those just real briefly.
2	MR. CALHOUN: Hold on. I'm going
3	to try to see if I can find these. Let's see,
4	hold on.
5	Well, I'm remembering while I'm
6	looking through here. A couple of the ones
7	and I might have screwed this up a little bit
8	because all of them. There were basically
9	finding number, I think 1 and then
10	CHAIR BEACH: Number 1, 2 and 13.
11	MR. CALHOUN: Yes. And number 13
12	is primarily x-ray issues. And what you'll
13	see is that actually changed our TBD. And the
14	TBD was recently revised and approved. And we
15	actually oh, here they are. Good. We did
16	exactly what was recommended.
17	And there was, for example, Table
18	3-1 has to do with default frequency of chest
19	x-rays. So that's really, in my opinion
20	that's not an SEC issue but it's a TBD issue.
21	And further, we actually did exactly what was
22	recommended It was unclear You guys made

1	some recommendations to clarify. We did
2	exactly what you asked us to.
3	And now, although I did kind of
4	throw it together and it would be prettier if
5	it was on a piece of paper, discusses that.
6	And then there was one further
7	issue that you guys might need to look at a
8	little bit more. But you had asked for claim
9	numbers to help, I don't know, verify some of
10	the statements that were in the TBD. And I
11	got those to you, but again that was only like
12	yesterday. And there was probably, if I look
13	here there's probably a good dozen of them
14	that I gave. And those x-rays as well.
15	Finding number 1 and or finding
16	number 1, let's see what that is.
17	MEMBER CLAWSON: I thought that was
18	the x-ray one was finding 1.
19	MR. CALHOUN: No, those were 13.
20	MEMBER CLAWSON: Oh, was it?
21	MR. CALHOUN: Yes. Hold on, I'm
22	getting there.

1	MEMBER CLAWSON: Oh, finding 13,
2	number 1 which is past
3	MR. CALHOUN: Right.
4	MEMBER CLAWSON: photographs
5	taken.
6	MR. CALHOUN: There were multiple
7	subs in 13. Okay. Finding 1 was bioassay
8	monitoring not adequately established.
9	CHAIR BEACH: And I think
LO	MR. CALHOUN: And you see, these
L1	actually I think number 1 was answered by
L2	our discussion here past 1993.
L3	CHAIR BEACH: This is Josie. It
L4	was. Grady, I think looking at number 4
L5	possibly. I guess what I'm going to suggest
L6	is that we close out the end date. I think we
L7	can agree with that, that after `93 we have
L8	the records available to do dose
L9	reconstruction.
20	But then I'd like to go ahead and
21	ask, I know we had tasked SC&A to look at the
22	Site Profile issues early on. But with the

new Site Profile issue that was issued on February 7 of this year are we already tasked -- and I guess this is a question for you, Ted. Are we tasked for SC&A to go back and in light of the new Site Profile issue re-look at those 13 Site Profile issues and then report out to the Work Group on those at a later date?

MR. KATZ: So we're not, but we can task that right now. Because I mean, it's pretty normal to have SC&A, once these are updated, to address SC&A comments and Work Group comments. It's pretty normal to have SC&A then follow up and say okay, it's all there and it's been done as agreed to, or whatever. Whatever they find. But yes, I think that's fine. We can just consider that tasked today.

MR. FITZGERALD: Yes. Ted and Josie, this is Joe. I think we're just trying to make the distinction between what we're identifying. And go back to the May 22 memo

NEAL R. GROSS

that Ron sent forward. And I'll defer to Ron for the details.

But we made a split in that memo on what we thought were SEC questions, not necessarily issues, but questions that Work Group ought to be clear on before proceeding. Of course the end date was the has taken front predominant one and And the others were clearly in the Site Profile vein.

But you know, separating Site Profile ones out just for clarity's sake I thought we had Ron, and maybe you can finger those very specifically. Several loose ends, remaining questions that NIOSH may have responded but not completely. Am I right about that?

DR. BUCHANAN: This is Ron. Okay, now we had 13 SEC issues and 13 Site Profile issues. The Site Profile issues, and these were addressed in a May 22 email of 2012. And in that email we outlined the SEC issues and

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

the Site Profile issues that NIOSH was responsible for.

Now, underlying that, the other side of the coin is that SC&A had not verified that the remaining Site Profile issues had been set aside with the revision in 2010. And that kind of got put on the back-burner.

So now we're faced with the fact that we have about six Site Profile issues. We need to go back to the 2013 TBD revision and see if they're satisfied.

I do not see any remaining Site Profile issue at this time that NIOSH is to address. And so that is kind of -- the ball is in our court on the Site Profile issues and seeing if they're satisfied by the 2013 revision.

Now, the SEC issues, I'd like to remind everyone that we had 13 of those and most of those were answered. However, number 4, number 11 and number 12 were not answered, have not been answered to date. And so we

NEAL R. GROSS

1	still have those even though the question of
2	the `93 end date has been settled. We still
3	have some pending SEC issues which we put
4	again on the back-burner because we were
5	interested in this end date.
6	And these had to do mainly with the
7	accuracy of the various neutron dosimeters and
8	the transfer of data, of the external data
9	from one database to another. And the
10	question of whether there was a need for
11	internal coworker models. Now, those three
12	are still hanging out there as far as the SEC
13	goes.
14	CHAIR BEACH: And Ron, this is
15	Josie. Would on those three, the SEC ones,
16	do we need a NIOSH answer on those?
17	DR. BUCHANAN: Yes, because
18	CHAIR BEACH: To move forward.
19	Okay.
20	DR. BUCHANAN: Yes, on number 4,
21	number 11 and number 12.
22	CHAIR BEACH: Okay.

DR. BUCHANAN: And these were in the May 22, 2012 email that SC&A sent out. This was an attached document to it.

CHAIR BEACH: Okay.

This MR. KATZ: Okay. is Ted, then. I mean given what Ron just said then, we can't close out the SEC at this meeting. We can close out the question of the end date and you can report out on that. And I quess we'll keep -- we can keep the session as is possibly vote but it won't be а session because we can't vote until we close out all the SEC issues.

But you can report out on this and the Board can ask you questions about this issue. You know, Grady qive can presentation on this, the whole nine yards on this one issue. And then you won't expect the Board to act on closing out the rest of the SEC until we hear what comes of these last three issues, assuming as Ron is implying that those all apply to this late

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

period as well. Because we already have an SEC before that.

CHAIR BEACH: Right.

This is Grady. MR. CALHOUN: Ι mean, isn't it -- to me it seems like we've got the records past 1993. And you know, if there is some massaging that needs to be done of the neutrons or whatever, I know that we have written some responses back to that. don't think that that's necessarily an I think that that's issue. а TBD dose reconstruction issue.

And, I don't know. It would be --I'd like to see this SEC issue closed if possible and continue on with TBD Because if Ι knew that there was some outstanding SEC issues before this meeting, I would have been working on those because that was my top priority.

MR. KATZ: Well, Ron, do you want to just respond to that? Because that's something I think everybody needs to

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

understand, what the TBD potential is or isn't.

DR. BUCHANAN: Yes. These were listed as SEC issues originally. And I feel that they should remain SEC issues until we resolve them.

Now, these involved the assignment of neutron dose. And Grady has responded to some of that in that the highest of the three were recorded and used readings for reconstruction. And our question is how do we know that that highest was correct. the verification of the data transfer between the many records system for external dose, which that number 11, Ι think was question of accuracy of the data. And then about the internal dosimetry, number 12, as far as a coworker model goes. So I think these have to be responded to before we can --I don't know that we can just shift those, the Site Profile issues.

CHAIR BEACH: No, I think we need a

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

response from NIOSH before we do that because that's where we left it.

MEMBER MUNN: This is Wanda. I would request that whatever we do, someone take the responsibility for making a very clear distinction between what we need to complete for our current problem and what we need to complete in terms of what we view as TBD issues.

If we don't have that clearly and if we don't agree on it then we're going to encounter this situation repeatedly where we think we've done something and we end up with the discovery that dangling we have participle somewhere. So if we could get a very clear decision of what we are going to an SEC issue and which are remaining outstanding, it would really be helpful for me rather than going back and sorting through all of our past transcripts to try to identify exactly what we had said earlier. that?

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	CHAIR BEACH: Wanda, this is Josie.
2	I can take the task of sending out the latest
3	memo that we've been talking about today, the
4	May 22, 2012. And the latest Site Profile
5	issue because those are very clear in what the
6	step forward or the process forward.
7	The biggest problem here is it's been a
8	year since we had a work call. Until we
9	decided to separate these out and then
10	you're right, these three kind of got lost
11	when we started thinking about the end date,
12	`93, and that got pushed forward. So.
13	MEMBER CLAWSON: I don't think they
14	got lost, Josie. I think what the thing was
15	is we were focusing in on the end date.
16	CHAIR BEACH: Right, right.
17	MEMBER CLAWSON: The issue with
18	that.
19	MEMBER ANDERSON: Yes, if the data
20	would have been complete then the other issues
21	weren't as critical for SEC.
22	MR. KATZ: Let me just suggest. I

mean, Grady, if as you -- we have, you know, not much time between now and the March Board But Grady, if you want to meeting. just consider these three issues that Ron has highlighted here that are remaining, if you want to consider in your presentation to the Board addressing why those may not be issues, I think that's fair game. And folks can respond to that in the Board meeting.

So if you want to address that that's fine and the Board can consider whether -- your arguments and then whatever people's responses are to that, whether those -- what governs here as to whether they're still SEC issues or they're not. But that'll be fine.

MR. CALHOUN: I'd really like to get the exact issues. I'm sure I've got them here in all this stuff. But since I obviously got confused and I thought that this was the evaluation of the end date, I'd really like to get those three objectives and I'll see what I can do by then.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	MEMBER MUNN: Yes, I'd agree it
2	would be helpful.
3	MR. KATZ: I'm not putting it on
4	you to have to do that. I'm just saying that
5	that's an option.
6	CHAIR BEACH: So again, this is
7	Josie. I'll go ahead and forward that, the
8	May 22 memo out which has those four
9	highlighted.
LO	MR. CALHOUN: I've got the May 22
L1	one and it only has I think it's only got
L2	number 1 and number 13.
L3	CHAIR BEACH: The one I have goes
L4	through all 11 and it highlights all the
L5	answers that are given to that date.
L6	MR. KATZ: Ron, wait. Ron is on
L7	the line. Ron, we just need you to send Grady
L8	the SEC issues you identified.
L9	DR. BUCHANAN: Yes, this is Ron. I
20	forwarded Josie a copy of the May 22 email and
21	also the Site Profile Matrix. And I updated
22	that to the current yesterday and highlighted

1	the action items for SC&A and for NIOSH. And
2	so, Josie, if you would forward that to Grady
3	then he would have a current copy to work from
4	that you and I, Joe, have been working from.
5	CHAIR BEACH: Yes, I will do that.
6	And I will also forward it to the Work Group
7	Members.
8	DR. BUCHANAN: And so, Grady, you
9	would have what we're looking at in front of
10	you there. And I highlighted in yellow the
11	areas that need to be addressed either by
12	NIOSH or by SC&A.
13	CHAIR BEACH: Actually, Ted, if it
14	works for you, I'll send it to you and then if
15	you could forward that to all the pertinent
16	parties.
17	MR. KATZ: Yes, I'll send it to the
18	whole Work Group and staff, right.
19	CHAIR BEACH: Okay.
20	MR. KATZ: And so then, I mean
21	Josie, it sounds like if it's okay with you
22	then I'll leave this, it's a possible vote.

But it would only be a vote if we somehow put to bed sufficiently with respect to as being SEC issues, these three items that Ron has highlighted as well. And if we don't then there won't be a vote but there can be whatever discussion is needed.

CHAIR BEACH: A discussion.

MR. FITZGERALD: I might add -this is Joe. We're talking number 4, number
11, number 12 in that May 22 piece. Just not
to confuse it with the other issues that are
more of a Site Profile nature.

And all we had at the time, you'll see this in the note. We posed the original issue. We got a NIOSH response. Then SC&A provided a response to that response. And that's where it has been since the Work Group has focused on the end date.

And these three issues aren't necessarily of the same ilk where one has to spend a lot of time doing analysis. I think it was asking for answers as far as what NIOSH

would in fact do on that particular point and why. And I think in those -- in some of these cases, the response wasn't deemed complete or adequate at the time. So that's kind of where it was left.

That's not to say that a lot of analysis per se, just sort of a complete answer as to what the path forward is going to be on that particular point, whether it's neutron dosimetry or on some other matter.

And these are issues, by the way, that were originally SEC issues pre `90, you know, in the SEC period that was voted by the Board last time. And they were carried forward as relevant issues past the current SEC period, is why they're here.

MEMBER MUNN: Yes, but the NIOSH memo that went out with the same cover letter at the May 22 Work Group. I think one of the things that's confusing is that that's the latest information that I have in my file. And it's the format, in written format the way

1	it is, it is kind of cumbersome to try to
2	identify what is still considered outstanding
3	and what isn't. I think, if we can helpful
4	something. Perhaps what Ron is going to be
5	sending out already has so that it stands out.
6	CHAIR BEACH: This is Josie. I
7	just sent that to Ted so you have it, Ted.
8	MR. KATZ: Great. I'll get it to
9	everybody right after this call.
10	CHAIR BEACH: Okay. So to wrap up
11	or to try to wrap up, we have a couple of
12	action items. SC&A is going to be tasked with
13	evaluating the latest version of the Site
14	Profile issue and marry it with the Site
15	Profile issues that we currently have, the 13.
16	And NIOSH will look at those three
17	items of the SEC relevant from the May 22 time
18	frame.
19	MEMBER ROESSLER: Josie, this is
20	Gen. I've been listening to this May 22
21	information. And the email I got is not I
22	just really don't know what to make out of it.

So when this is sent around again, I think I need to see some pretty clear conclusions that come along with it.

MR. KATZ: So Gen, Ron says he highlighted the three issues, the 4, 11 and 12. We'll send those around. He -- not necessarily responded to those yet. He may respond to those at the Board meeting.

MEMBER ROESSLER: Okay, okay.

MR. KATZ: Okay?

CHAIR BEACH: Okay. This is Josie again. Thank you for your patience. When we don't meet for over a year and we had two lists going it does really get complicated when you try to reconcile it and then vote on something. So I appreciate everybody's patience here as we sort this all out again.

MR. KATZ: Yes, it's okay. And we have an hour set aside for the BNL discussion. So, you know, there's gracious amount of time to at least get things clear at the Board meeting, if not resolve them.

NEAL R. GROSS

1	CHAIR BEACH: Okay. So I have
2	nothing else unless anybody else does.
3	MEMBER MUNN: Not me.
4	MEMBER ROESSLER: I'm done.
5	CHAIR BEACH: Then I'd say we can
6	adjourn this meeting. Thank you.
7	(Whereupon, the above-entitled
8	matter went off the record at 3:36 p.m.)
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	